New Delhi, Jan 9 (PTI) Pharma major Lupin Ltd on Thursday said it has received tentative approval from the US health regulator to market its generic version of Ivacaftor oral granules used in treatment of cystic fibrosis.

The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Ivacaftor oral granules of strengths 25 mg, 50 mg, and 75 mg per unit dose packet, Lupin said in a statement.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for January 9, 2025 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

These are the generic equivalent of 'Kalydeco' oral granules, 25 mg, 50 mg, and 75 mg, of Vertex Pharmaceuticals Incorporated.

"Lupin is the exclusive first-to-file for this product and may be eligible for 180 days of generic drug exclusivity," the company said, adding that the product would be manufactured at its Nagpur facility.

Also Read | Shillong Teer Results Today, January 9 2025: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

Ivacaftor oral granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for the treatment of cystic fibrosis (CF) in patients aged four months and older who have at least one mutation in the 'CFTR' gene that is responsive to Ivacaftor.

Citing IQVIA MAT November 2024 data, the company said Ivacaftor oral granules, 25 mg, 50 mg and 75 mg had an estimated annual sale of USD 51 million in the US.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)